At 14.0% CAGR, Asia Pacific Therapeutic Vaccines Market is Projected to be Worth US$ 85,862.88 Thousand by 2031, says Business Market Insights

According to Business Market Insights' research, the Asia Pacific therapeutic vaccines market was valued at US$ 34,213.87 thousand in 2024 and is expected to reach US$ 85,862.88 thousand by 2031, registering a CAGR of 14.0% from 2024 to 2031. Increasing investments and funding for vaccine development and rising prevalence of chronic conditions are among the critical factors attributed to drive the Asia Pacific therapeutic vaccines market.

Therapeutic vaccines stimulate the immune system to aid the treatment of cancer, autoimmune disorders, and chronic infections. The growing investments and funding for vaccine development drive the expansion of the therapeutic vaccines market, fostering innovation and accelerating the development of novel treatments for chronic diseases. Over the past decade, global investments in vaccine research and development (R&D) have increased significantly, with governments, private institutions, and pharmaceutical companies recognizing the importance of therapeutic vaccines in addressing unmet medical needs. They are investing in new technologies, platforms, and approaches to develop innovative therapeutic vaccines, particularly for diseases that have limited therapeutic options, such as certain cancer types and viral infections. For instance, in 2021, GlaxoSmithKline (GSK) allocated US$ 6.46 billion (£5.3 billion) toward R&D, extending a robust budget to establish a pipeline featuring 43 medicines and 21 vaccines; with nearly 50% of these drugs target infectious diseases. This pipeline includes ongoing vaccine development programs aimed at providing protection against COVID-19 and influenza, as well as innovative therapeutic vaccine approaches for chronic hepatitis B virus infections, building upon decades of achievement in prophylactic vaccines. Initiatives entailed by its pipeline leverage diverse technologies to proactively combat diseases across all age demographics.

In 2025, AstraZeneca announced plans to invest US$ 2.5 billion in research and manufacturing in Beijing as part of its strategy to strengthen its presence in the Chinese market. This decision follows recent controversies, including abandoning plans for a UK vaccine plant and the detention of executives in China. The company has already invested nearly US$ 10 billion in 12 acquisitions in China, including the US$ 1.2 billion purchase of Gracell Biotechnologies, which focuses on cell therapies for cancer and autoimmune diseases. In 2023, South Korea's Ministry of Health and Welfare plans to invest over KRW 250 billion in the bio-health sector to boost cancer treatment research and enhance responses to infectious diseases. This will include developing new drugs, vaccines, and diagnostic technologies.

Thus, the increasing investments and funding for vaccine development contribute significantly to the growth of the therapeutic vaccines market.

On the contrary, regulatory challenges hamper the growth of Asia Pacific therapeutic vaccines market.

Based on product, the Asia Pacific therapeutic vaccines market is bifurcated into cancer vaccine, infectious disease vaccine, and others. The cancer vaccine segment held 100.0% market share in 2024, amassing US$ 34,213.87 thousand. It is projected to garner US$ 84,458.80 thousand by 2031 to register 13.8% CAGR during 2024–2031.

By technology, the Asia Pacific therapeutic vaccines market is bifurcated into allogenic vaccine and autologus vaccine. The allogenic vaccine segment held 100.0% share of Asia Pacific therapeutic vaccines market in 2024, amassing US$ 34,213.87 thousand. It is projected to garner US$ 85,341.88 thousand by 2031 to expand at 13.9% CAGR from 2024 to 2031.

In terms of end user, the Asia Pacific therapeutic vaccines market is categorized into hospitals, clinics, and others. The hospital segment held 61.9% share of Asia Pacific therapeutic vaccines market in 2024, amassing US$ 21,164.26 thousand. It is projected to garner US$ 54,132.16 thousand by 2031 to expand at 14.4% CAGR from 2024 to 2031.

Based on country, the Asia Pacific therapeutic vaccines market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Our regional analysis states that Australia captured 66.5% share of Asia Pacific therapeutic vaccines market in 2024. It was assessed at US$ 22,745.42 thousand in 2024 and is likely to hit US$ 55,825.80 thousand by 2031, registering a CAGR of 13.7% during 2024 to 2031.

Key players operating in the therapeutic vaccines market are Dendreon, BioNTech SE, Serum Institute of India Pvt. Ltd, Merck & Co Inc, Amgen Inc, ISA Pharmaceuticals BV, INOVIO Pharmaceuticals Inc, Transgene SA, THERAVECTYS SA, and CureVac SE, among others. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com